SARS-CoV-2 Recombinant Antigens

Serology testing is an important tool for monitoring the evolution of an outbreak. Serology tests that detect neutralizing antibodies are particularly useful for evaluating vaccine-induced protective immunity. As new SARS-CoV-2 variants emerge with mutations in the spike S protein, their potential to become “escape mutants” and negatively impact vaccine efficacy needs to be evaluated through neutralization testing.

Meridian’s new panel of SARS-CoV-2 mutant recombinant antigens represent the major circulating mutant strains and are suitable for use in neutralization studies and as controls in serology assays. They complement the existing range of high-performing SAR-CoV-2 wild-type antigens, several of which are in current EUA approved COVID-19 IgG/IgM serology tests.

All antigens are expressed in insect cells unless otherwise indicated.





Related products

SARS-CoV-2 Recombinant Antigens
MAbs to SARS-CoV-2
COVID-19